Glutathione is a naturally occurring tripeptide. It plays an important role in the body's antioxidant defense systems. It is synthesized in cells throughout the body, with the liver contributing significantly to glutathione metabolism and circulating levels.
Glutathione is marketed in oral dietary supplements and has been studied in topical formulations. However, no FDA-approved glutathione drug products are available in the United States, including injectable products. Evidence supporting proposed benefits varies by formulation, and several uses remain inadequately established.
In 2026, the CDC and FDA investigated adverse events associated with injectable glutathione compounded using a dietary supplement-grade ingredient linked to elevated endotoxin levels. The CDC reported more than 25 illnesses across at least four states, with at least three hospitalizations. The FDA separately reported adverse events involving at least 30 patients. The investigation highlights the importance of ingredient suitability and quality controls when preparing sterile injectable products.
What Is Glutathione?
Glutathione (γ-glutamyl-cysteinyl-glycine) is a tripeptide composed of three amino acids: glutamate, cysteine, and glycine. It exists primarily in two forms:
- Reduced glutathione (GSH): The reduced form involved in antioxidant defense and cellular redox regulation.
- Oxidized glutathione (GSSG): The oxidized form produced when glutathione participates in reactions involving oxidative compounds.
Glutathione supports several cellular processes. It serves as a substrate for enzymes such as glutathione peroxidases and glutathione S-transferases, which contribute to antioxidant defense and the metabolism of certain compounds.
Glutathione is present in many tissues, including the liver, and is important for maintaining normal cellular function.
Important distinction: The fact that glutathione occurs naturally in the human body does not establish the safety or effectiveness of every glutathione formulation. Injectable products require ingredients appropriate for sterile administration. The FDA specifically warns against using dietary supplement-grade glutathione to compound injectable drugs because such ingredients may contain harmful contaminants, including endotoxins.
Glutathione: What Does the Research Say?
Researchers investigate glutathione in relation to oxidative stress, skin pigmentation, and other biological processes. However, research findings must be interpreted according to the formulation, route of administration, study design, and quality of the available evidence.
Intravenous (IV) Glutathione
Research on intravenous glutathione for skin lightening remains limited, and the available evidence does not establish a favorable benefit-risk profile for this use.
A systematic review published in the International Journal of Dermatology in 2025 identified only one placebo-controlled trial of intravenous glutathione for skin lightening. In that study, 6 of 16 participants receiving glutathione (37.5%) showed improvement, compared with 3 of 16 participants (18.7%) receiving placebo. The difference did not reach conventional statistical significance.
The review also noted that the reported improvement was not sustained in most participants after treatment stopped. Considering the limited evidence and safety concerns, the authors concluded that intravenous glutathione is contraindicated for skin-lightening purposes.
Separately, the FDA's 2026 safety alert described adverse events associated with injectable glutathione compounded using a dietary supplement-grade ingredient. Reported symptoms included fever, chills, pain, dizziness, and signs of shock or sepsis-like illness. These reports reinforce the importance of ingredient quality and appropriate manufacturing controls.
Other Routes of Administration
| Route | Summary of evidence | Major limitations |
|---|---|---|
| Oral | Some clinical studies report reductions in melanin index. | Studies are limited, and long-term efficacy remains uncertain. |
| Topical | Some studies report changes in skin pigmentation with specific formulations. | Results may depend on concentration and formulation; findings cannot be generalized to other routes. |
| Inhaled | Investigated in respiratory conditions, including cystic fibrosis. | Findings from individual studies do not establish broad clinical benefits. |
| Intravenous | Limited evidence for skin lightening, with documented safety concerns for certain compounded products. | Benefits are not well established, and contamination can cause serious harm. |
A 2025 systematic review found some positive findings in oral and topical skin-lightening studies but also identified limitations in the evidence and variability in study quality. These findings should not be interpreted as proof that every formulation is effective or appropriate for clinical use.
Evidence Limitations
The available research has several important limitations:
- Some studies involve small participant groups.
- Formulations, concentrations, and administration routes differ across studies.
- Follow-up periods may be insufficient to establish long-term outcomes.
- Results from topical or oral formulations cannot establish the safety or effectiveness of injectable products.
- Findings related to skin pigmentation do not establish benefits for other medical or cosmetic purposes.
For these reasons, claims about skin lightening, anti-aging, detoxification, or other clinical outcomes should not be presented as established benefits without adequate supporting evidence.
Glutathione FDA Status and Safety Information
FDA Approval Status
None of the glutathione drug products have been approved by the FDA in the United States. This includes glutathione products for injection.
Glutathione is also included in the FDA's Category 1 list of bulk drug substances nominated for potential use in compounding under Section 503A. This means that the substance is the subject of evaluation within the FDA's compounding program, but that it is not FDA-approved, nor that any formulation containing it may lawfully be compounded.
Drugs that have been compounded are not FDA-approved products, and the FDA does not verify their safety, efficacy, and quality through the drug-approval process prior to marketing. Whether a particular compounded preparation satisfies applicable legal requirements depends upon the circumstances and applicable regulations.
Injectable Glutathione Safety Investigation
In 2026, public health agencies investigated illnesses associated with injectable glutathione compounded using dietary supplement-grade glutathione. The CDC reported the following in its September 2026 update:
| Details of investigation | Reported information |
|---|---|
| States affected | Texas, Washington, Florida and New York |
| Reported illnesses | More than 25 people |
| Reported hospitalizations | At least 3 |
| Critical illnesses | 1 patient required intensive care for shock and abnormal blood clotting |
| Suspected concerns | High levels of endotoxin in injectable products compounded using dietary supplement-grade glutathione |
The CDC stated that the investigation was ongoing and that the number of affected people and states could change. Separately, the FDA reported adverse events involving at least 30 patients and identified a dietary supplement-grade glutathione ingredient associated with the investigation. These figures come from separate agency reports and should not be treated as interchangeable counts of confirmed cases.
Symptoms and Reported Recalls
Symptoms reported in association with the investigation included fever, chills, body aches, headache, nausea, dizziness, and low blood pressure. Excessive endotoxin exposure can cause severe reactions that require emergency medical care.
The FDA has published recall notices involving specific lots of compounded glutathione products, including:
These notices concern specific products or lots. They do not establish that every glutathione product is affected. Consumers and healthcare professionals should consult the individual notices for affected lot numbers, package sizes, and instructions.
Why Ingredient Quality Matters
The identified safety concern is not simply a question of product strength. Ingredients intended for dietary supplements may not meet the requirements for use in sterile injectable drugs, including controls relevant to endotoxin contamination.
The FDA advises compounders not to use dietary supplement-grade glutathione to prepare injectable products. It also emphasizes that product quality must be maintained throughout ingredient sourcing, preparation, and release rather than relying on finished-product testing alone.
A stated strength of 2,000 mg does not establish product quality, safety, or clinical effectiveness.
